CTOs on the Move


 
InnFocus, Inc., an early stage company pioneering a microsurgical solution for glaucoma.InnFocus is an ophthalmology company founded in 2003 with extensive biomaterials experience that develops and provides next generation products for glaucoma surgery. Glaucoma is a disease for which there is no cure, is the second leading cause of blindness in the world and afflicts an estimated 60 million people worldwide.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

InnFocus raised $33.9M on 12/23/2015

Similar Companies

omnipath diagnostics

omnipath diagnostics is a Canoga Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CHRISTUS Health

At CHRISTUS Health, we pride ourselves on serving our communities, our patients and our associates as more than a health care provider.

Lantheus

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., which is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. LMI is headquartered in North Billerica, Massachusetts, and has offices in Puerto Rico, Canada and Australia.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.

DermOne

DermOne is a leading provider of comprehensive dermatology services through a fast-growing network of neighborhood skin care centers. Our goal is to make high-quality, affordable dermatology care accessible to everyone. We offer more providers, more services and more locations which means we are there for you when you need us! By delivering the highest standard of personal care, we strive to ensure the best experience for each patient. As we continue to grow, we look forward to bringing our unique skin-care approach to even more individuals and neighborhoods across the country––ensuring that everyone has access to high-quality dermatology care.